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A B S T R A C T
Thermal injury promotes tissue inflammation and pain, which is difficult to control. Different peripheral me-
chanisms seem to be involved in burn pain, such as free radical-induced damage, but further study is still needed
to understand how oxidant substances induced nociceptor sensitization. The transient receptor potential ankyrin
1 (TRPA1) is an ion channel activated by oxidants substances, and it could be sensitized after tissue in-
flammation. This study evaluated the TRPA1 involvement in nociception and inflammation produced by a
thermal injury model. Male Wistar rats were used. The concentration of the TRPA1 antagonist (HC-030031,
0.05%) on base cream was chosen using allyl isothiocyanate intraplantar test. Then, the base cream containing
HC-030031 was tested on the thermal injury model (induced by warm water immersion of hind paw, under
anesthesia), and silver sulfadiazine (1%) was used as a positive control. Cream treatments on the hind paw were
done daily (200mg/paw) for 6 days after thermal injury. Also, nociception (static and dynamic mechanical
allodynia, heat allodynia, and spontaneous pain) or edema were evaluated. On day 6, inflammatory and oxi-
dative parameters were assessed. The base cream containing HC-030031 produced antinociceptive and anti-
inflammatory effects (reduced the edema and inflammatory cells infiltration) and decreased the levels of hy-
drogen peroxide, or superoxide dismutase and NADPH oxidase activities after thermal injury. Thus, this study
showed the involvement of the TRPA1 receptor in the nociception and inflammation caused by thermal injury
and suggested that TRPA1 antagonists might be useful as novel treatments for pain and inflammation by topical
application.
1. Introduction
Burns are lesions damaging organic tissues, usually caused by ex-
posure to external agents such as solar radiation, contact with hot
surfaces and flames, or even contact with liquids at high temperature
(Bishop et al., 2007; Evers et al., 2010; Treede et al., 2015). Moreover,
the type of burn, according to the depth and extent of the lesion, are
factors that will directly influence the prognosis of the thermal injury
and the form of pain which will be observed (McIntyre et al., 2016).
Considering this, burns induced by liquids at high temperatures are
usually first-degree lesions. In such cases, the primary symptoms ob-
served are edema and pain, with intense inflammation and possible skin
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desquamation (3 to 7 days after the induction of the lesion) (Monstrey
et al., 2008; Piccolo et al., 2008; Serrano et al., 2015).
Pain is one of the most incapacitating symptoms and represents a
challenge after burn injury, due to the control difficulty, considering
the currently available drugs in the clinic (Cuttle et al., 2009;
McGaraughty et al., 2010; Richardson and Mustard, 2009). In patients
with burns, the injury treatment during and after wound healing is still
far from ideal, especially for pain control (Cuttle et al., 2009;
Richardson and Mustard, 2009). In the case of first-degree burns, acute
pain is accompanied by edema and redness of the affected area and is
usually treated with the use of analgesics (ibuprofen, naproxen or even
paracetamol) by oral administration (Walls et al., 2017). However,
these medicines still did not induce complete relieve of inflammatory
pain observed after burn injury (James and Jowza, 2017), in this sense
it is interesting to investigate other mechanisms that could be involved
in this type of pain (McIntyre et al., 2016).
One of the mechanisms involved in the inflammatory response and
exacerbated edema observed in thermal lesions is the augmented pro-
duction of reactive oxygen species (i.e., hydrogen peroxide), due to the
activation of enzymes NADPH oxidase and superoxide dismutase (SOD)
in inflammatory cells, such as neutrophils and macrophages (Hoşnuter
et al., 2004; Parihar et al., 2008). Remarkably, oxidative compounds
could also lead to the activation of receptors involved in pain trans-
duction, such as transient receptor potential ankyrin 1 (TRPA1)
(Hoşnuter et al., 2004; Parihar et al., 2008; Raisinghani et al., 2011).
The TRPA1 channel is a polymodal cellular sensor, which forms a
non-selective cation channel, being permeable mainly to calcium
(Levine and Alessandri-Haber, 2007). This receptor is expressed in
peptidergic sensory fibers along TRP vanilloid 1 (TRPV1) (Geppetti
et al., 2008). Moreover, TRPA1 is the primary target of many different
irritant stimuli, such as allyl isothiocyanate (AITC, contained in mus-
tard oil and wasabi) or cinnamaldehyde (present in cinnamon), and a
series of endogenous oxidant molecules produced at sites of in-
flammation and tissue injury, such as reactive oxygen (ROS, as hy-
drogen peroxide) and nitrative (RNS) species (Andersson et al., 2008;
Baraldi et al., 2010; Sawada et al., 2008; Taylor-Clark and Undem,
2010; Trevisani et al., 2007). Thus, the interaction between the TRPA1
channel and these highly reactive compounds is of high relevance for
the recognition of cellular damage, especially during inflammatory and
neuropathic events (Bang and Hwang, 2009; Hinman et al., 2007;
McGaraughty et al., 2010; Trevisan et al., 2016).
Also, TRPA1 is emerging as a significant nociceptive mechanism in a
variety of inflammatory pain models such as those induced by carra-
geenan, formalin, and complete Freund adjuvant injection (da Costa
et al., 2010; Eid et al., 2008; McGaraughty et al., 2010; Petrus et al.,
2007) or gout models (Moilanen et al., 2015; Trevisan et al., 2013,
2014). Previously, it was described that TRPV1 and TRPA1 could be
activated by lipid oxidized agonists in the spinal cord after burn injury
producing mechanical and thermal hypersensitivity (Green et al.,
2016), however, to the best of our knowledge, the role of peripheral
TRPA1 in burn-induced nociception was not investigated until now. It is
well known that TRPA1 is activated by reactive species and sensitized
by inflammatory mediators, being able to participate in the main-
tenance of the inflammatory pain process (Eid et al., 2008;
McGaraughty et al., 2010; Petrus et al., 2007). Moreover, the effect of a
topical TRPA1 antagonist in an inflammatory model of pain has not
been observed yet. As the model of burn injury in rats produce an in-
flammatory reaction that could be treated locally, we choose this model
to test the possibility that blocking the TRPA1 in the periphery could be
sufficient to reduce the burn-induced nociception and inflammation.
Regarding this, the current study aimed to evaluate the effect of a
TRPA1 antagonist topical treatment in the nociception and inflamma-
tion induced by a thermal lesion model in the hind paw of rats.
2. Material and methods
2.1. Animals
Experiments were performed in adult male Wistar rats (150–200 g,
8–10weeks) bred in-house. The animals were kept in ventilated cages
(5 per cage) with wood shaving bedding and nesting material at con-
trolled temperature (22 ± 2 °C) and a 12 h light/dark cycle (lights on
7:00 a.m. to 7:00 p.m.). It was provided the laboratory standard ani-
mal's food (Puro Lab 22 PB pelleted form, Puro Trato, Rio Grande do
Sul, Brazil) and tap water ad libitum. The animals were habituated in
the experimental room for at least 1 h before each behavioral task. The
experiments reported in this study were performed according to the
ethical guidelines to investigate pain-like symptoms in conscious ani-
mals set by the International Association for the Study of Pain
(Zimmermann, 1983). The study was approved by the Committee on
the Use and Care of Laboratory Animals at University of the Extreme
South of Santa Catarina (Unesc), under protocol number 020/2015–2
with an addendum to the protocol, number 008/2015–2. The beha-
vioral studies followed the Animal Research: Reporting In Vivo Ex-
periments (ARRIVE) guidelines (McGrath and Lilley, 2015). The ex-
perimenter was blinded to drug administration. The protocol of thermal
injury model in this study was repeated twice in different days of ex-
periments (using two blocks of animals, one with 4 animals, and an-
other with 3 animals per treated group), but each animal was used only
one time. The experiments were performed between 7:00 a.m. and
5:00 p.m.
2.2. Reagents
Otherwise indicated, reagents were acquired from Sigma-Aldrich
Chemical Co. (St. Louis, MO, USA). The treatments (HC-030031 or
silver sulfadiazine) were incorporated into Lanette cream (Lanette® wax
12.0 g; solid vaseline 11.0mL, propyleneglycol 7.0mL; parabens solu-
tion preservative 3.3 g; imidazolidinyl urea preservative solution 50%;
distilled water for 100 g) (Silva et al., 2013). Lanette cream (base
cream) without HC-030031 was used as vehicle and silver sulfadiazine
in the 1% concentration was used as a positive control (Silva et al.,
2013; Souza et al., 2017). The HC-030031 was tested at three different
concentrations (0.005, 0.05, and 0.5%) based on concentrations that we
have previously subcutaneously injected in the hind paw (Trevisan
et al., 2013).
2.3. Nociception and edema model induced by intraplantar injection of
AITC
Firstly, to determine the indicated concentration of HC-030031 (a
TRPA1 antagonist) to be used in the thermic injury model, we used the
AITC-induced nociception and edema model (Trevisan et al., 2013). For
that, we performed an initial set of experiments where each animal
received 200mg/paw of base cream containing HC-030031 and control
group received only base cream. Animals were topically treated (right
hind paw, 10min before the test) with a base cream containing HC-
030031 (0.005; 0.5 or 0.5%). The animals were divided into four
groups (base cream, base cream containing 0.005% of HC-030031, base
cream containing 0.05% of HC-030031, or base cream containing 0.5%
of HC-030031) with five animals in each group. After 10min of the
topical administration, AITC was injected subcutaneously at a dose of
1 nmol/paw (100 μL volume) into the right hind paw. The nociceptive
behavior (paw licking or flinching) was timed for 5min after AITC in-
jection. Also, 15min after AITC injection, the paw edema was measured
using a digital caliper as described before (Trevisan et al., 2013). Be-
cause the base cream containing 0.05% of HC-030031 reduced AITC-
induced nociception and edema, we used this HC-030031 formulation
to perform the further experiments using the thermal injury model in
rats.
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2.4. Thermal injury model
Rats received a scald burn on the right hind paw as described pre-
viously (Gao et al., 2010; Silva et al., 2013). Following the measure-
ment of baseline responses, the animals were anesthetized with keta-
mine (90mg/kg, i.p.) and xylazine (3mg/kg, i.p.) (Klafke et al., 2016),
and the right hind paw was placed and held in 70 °C water for 5 s
(considered as a first burn model). In the sham procedure group (con-
trol group), the right hind paw was exposed to 37 °C water for 5 s. After
the stimulus was applied, the rat was returned to the home cage to
recover from anesthesia. The nociceptive behavior and paw edema
were measured on days 1 to 6 after the induction of thermal injury or in
the control group. The treatments were performed immediately after
the injury (day 0), and then for a further 5 days period, and there was
no treatment on the 6th day after the thermal injury. For the treatment,
rats were divided into five groups (n=7 animals for each group)
known as Control (no injury); No treatment (thermal injury without
treatment); Vehicle (thermal injury plus base cream); Sulfadiazine 1%
(thermal injury plus base cream containing silver sulfadiazine 1%); and
HC-030031 0.05% (thermal injury plus base cream containing HC-
030031 0.05%).
2.5. Nociception assessment
The antinociceptive effect of treatments tested was evaluated
through several nociceptive parameters: static mechanical allodynia,
dynamic mechanical allodynia, thermal allodynia, and spontaneous
nociception. The nociception was measured before (baseline values)
and once a day, from day 1 to 6 after thermal injury (Fig. 1).
2.5.1. Static mechanical allodynia
To estimate the static mechanical allodynia, rats were individually
placed in clear Plexiglas boxes (9 cm×7 cm×11 cm) on elevated wire
mesh platforms to access the ventral surface of the hind paws (Chaplan
et al., 1994; Silva et al., 2013). The 50% withdrawal threshold was
determined using the up-and-down method (Dixon, 1980). In this
paradigm, the test was initiated with the 6 g von Frey filament. We used
seven distinct von Frey filaments: 15, 10, 8, 6, 4, 2 or 1 g. Stimuli were
always presented consecutively; either ascending or descending.
Withdrawal thresholds were verified at several time points after
thermal injury (from days 1 to 6) and were compared with the baseline
values (before thermal injury). The results were expressed as noxious
mechanical paw withdrawal threshold (s).
2.5.2. Dynamic mechanical allodynia
The dynamic response to a non-noxious mechanical stimulus was
measured as described previously (Jaggi and Singh, 2011; Silva et al.,
2013). The response to a soft paintbrush has been described as allo-
dynia because naive rats rarely withdraw the paw from this stimulus.
Rats were placed in clear Plexiglas boxes (9 cm×7 cm×11 cm) on
elevated wire mesh platforms to access the ventral surface of the hind
paws. After that, a smooth paintbrush stimulus was used to rub the
plantar area of hind paw from the heel to the toes for a maximum of
15 s. A paw withdrawal response within 15 s was considered as dy-
namic mechanical allodynia. The results were expressed as innocuous
mechanical paw withdrawal latency (s).
2.5.3. Thermal heat allodynia
The paw immersion test was used to observe the response of rats to
non-noxious heat. Briefly, rats were gently handled, and their right paw
was dipped into a bath containing water at 30 °C (Silva et al., 2013;
Takahashi et al., 2003). The paw withdrawal latency was recorded with
a chronometer. The maximum exposure to the stimulus time was 20 s.
The results were expressed as noxious thermal paw withdrawal latency
(s).
2.5.4. Spontaneous nociception
The spontaneous nociceptive behavior of rats was evaluated for
5min with a chronometer (Silva et al., 2013; Weissman-Fogel et al.,
2008). The nociceptive response was determined as paw licking or
flinching. Rats were placed in transparent acrylic boxes
(20 cm×20 cm×20 cm) to observe the spontaneous nociception time.
2.6. Inflammation and oxidative stress assessment
2.6.1. Edema development
The paw edema induced by thermal injury was considered as the
paw thickness increase, measured with a digital caliper (Silva et al.,
2013; Trevisan et al., 2013). Paw thickness was verified at several time
points (1 to 6 days) after thermal injury and compared to baseline va-
lues (before thermal damage). The results were expressed as paw
thickness (mm). The caliper position was done in all the measures in the
center of the hind paw, and the same experimenter observed the paw
thickness in all time points.
2.6.2. Parameters of inflammation and oxidative stress
After 6 days of the thermal injury induction, the animals were eu-
thanized by chemical method (pre-anesthetized with diazepam 5mg/
kg/mL and after that was administered thiopental 50mg/kg/mL i.p.).
The samples of rats hind paw skin (we used the hind paw inferior
surface) were removed to evaluate inflammatory and oxidative stress
parameters and were processed separately for each analysis. We tested
the animals until the 6th day after lesion because in previous studies of
our group we observe that in this time point we could analyze the
markers of inflammation and oxidative stress, after 6 days we noted a
reduction in these parameters (Silva et al., 2013).
2.6.3. Leukocyte infiltration markers
To estimate the leukocyte infiltration after thermal injury, paw skin
samples were collected to measure the myeloperoxidase (MPO) and N-
acetyl-β-D-glucosaminidase (NAGase) activities. Firstly, samples were
obtained and homogenized with a motor-driven homogenizer in sodium
acetate buffer containing 0.5% HTAB and kept at 4 °C, centrifuged and
the supernatant was then collected for assays. For the MPO activity
measurement, the supernatant was incubated with acetate buffer and
3,3′5,5′ tetramethyl-benzidine for 3min at 37 °C. The color formed was
assessed by a spectrophotometer at 630 nm. For the measurement of
NAGase activity, the supernatant was incubated with 4-nitrophenyl N-
acetyl-β-D-glucosaminide and citrate buffer at 37 °C for 1 h. The reac-
tion was stopped by ice and with glycine buffer, and color development
Fig. 1. Timeline of the nociception evaluation per-
formed before the thermal injury in rats to assess the
baseline values of nociceptive parameters and time-
line from day 1 to 6 after thermal injury. The rats
were evaluated daily through several nociceptive
parameters as the following sequence: (1) Static
mechanical allodynia, (2) Dynamic mechanical al-
lodynia, (3) Thermal allodynia, and (4) Spontaneous
nociception.
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was measured at 405 nm. The absorbance of all reactions was measured
in a Fisher Biotech Microkinetics Reader Bt 2000 microplate reader.
The values were expressed as optical densities, corrected for the protein
content, which was measured according to Bradford (1976).
2.6.4. Histology
Paw samples were collected and fixed for 14–16 h in alfac solution
(16:2:1 mixture of ethanol 80%, formaldehyde 40%, and acetic acid).
Samples were embedded in paraffin wax, sectioned at 4 μm and stained
with hematoxylin-eosin (H&E). A representative area was selected for
qualitative light microscopic analysis of the inflammatory cells detec-
tion with a 200× and 400× objectives under an optical microscope
(Eclipse 50i, Nikon, Melville, NY). The images were recorded with the
Nikon (Sight DS-5M-L1, Melville, NY, USA). For the inflammatory cell
count, six random fields from H&E-stained slides were observed to
quantify the inflammatory cells (polymorphonuclear leukocytes) pre-
sence in dermis layer at the paw tissue using NIH Image J 13.6 software
(NIH, Bethesda, MD, USA) at a magnification of 200× (Chibli et al.,
2014; Lee et al., 2013; Oliveira et al., 2014; Song et al., 2008). The
results were expressed as number of polymorphonuclear cells per field.
2.6.5. Determination of hydrogen peroxide levels, NADPH oxidase and
superoxide dismutase (SOD) activity
The samples were homogenized in phosphate buffer, containing
sodium azide at 4 °C for 30 s. The homogenate was centrifuged and the
supernatant obtained was used to determine the H2O2 levels (Nakamura
et al., 1998; Trevisan et al., 2013). The H2O2 levels were expressed as
μmol of H2O2, based on a standard curve of HRPO-mediated oxidation
of phenol red by H2O2, and corrected by the protein content (in mg) of
the paw skin sample analyzed (Bradford, 1976).
The activity of NADPH-oxidase was observed in paw skin samples
using a commercially available assay kit (CY0100, cytochrome re-
ductase, NADPH Assay Kit, Sigma-Aldrich). The results were expressed
as U/mL/mg of protein (Bradford, 1976).
To analyze the SOD activity (Bannister and Calabrese, 1987), paw
skin samples were homogenized in Tris-HCl buffer and centrifuged at
4 °C for 3min. Then, the samples were incubated with adrenaline and
glycine buffer at 33 °C. The absorbance was measured at 480 nm and
monitored for 5min. The reaction was read in a microkinetic reader
(Fisher Biotech BT, 2000). The results were expressed as U/mL/mg of
protein, and protein content was measured by the method of Bradford
(1976).
2.7. Statistical analysis
All values were expressed as mean ± S.E.M and analyzed by
Student's t-test, one-way or two-way analysis of variance (ANOVA)
followed by Bonferroni's post hoc test when appropriate. All analyzes
were carried out using GraphPad 5.0 Software (San Diego, CA, USA)
and ImageJ software (western blot and inflammatory cells count). The
P < 0.05 values denote significant difference between groups.
3. Results
3.1. Topical application of HC-030031 decreased nociception and edema
caused by AITC intraplantar administration
It was observed that a base cream containing HC-030031 (0.05 and
0.5%) decreased the nociceptive and edematogenic responses evoked
by intraplantar injection of the TRPA1 agonist (AITC, 1 nmol/paw),
with a inhibition of 72 ± 13 and 76 ± 6% for the nociception, and
76 ± 8 and 60 ± 8% to the edematogenic effect, respectively (Fig. 2A
and B). As no significant differences were identified between these two
concentrations, the base cream containing HC-030031 (0.05%) for-
mulation was chosen to perform further the study of TRPA1 antagonist
effect on the inflammatory pain model caused by thermal injury in rats.
3.2. TRPA1 antagonism induced antinociceptive effects in a thermal injury
model in rats
After thermal injury induction, static mechanical allodynia was
detected from day 1 to 6, when compared to control animals. It was
characterized by a reduction in the paw withdrawal threshold eval-
uated through von Frey filaments (15 g for control group vs. 1.32 g for
no treated group, observed on day 6 after thermal injury; Fig. 3A).
Furthermore, rats that received topic treatment with HC-030031
(0.05%) showed an anti-allodynic effect from day 4 to 6 after treat-
ment, with an inhibition of 43 ± 10% on the 6th day after thermal
injury (Fig. 3A). Silver sulfadiazine (1%) demonstrated a similar effi-
cacy when compared to HC-030031 treatment, which presented an
inhibition of 44 ± 15%, at 6 days after the thermal injury (Fig. 3A).
In comparison to the control group, the rats that received thermal
injury and were not treated showed dynamic mechanical allodynia
(from 1 day to 6). Thus, animals with thermal injury but without
treatment reduced the paw withdrawal latencies in response to a
paintbrush (15 s for control group vs. 4.85 s for no treated group, ob-
served on day 5 after thermal injury; Fig. 3B). Also, application of HC-
Fig. 2. (A) Antinociceptive or (B) antiedematogenic effect of a TRPA1 an-
tagonist (HC-030031) by topical treatment after the intraplantar injection of
AITC in rats. AITC (a TRPA1 agonist, 1 nmol/site) was injected 10min after the
topical administration of base cream (vehicle, 200mg/paw) or base cream
containing HC-030031 (0.005, 0.05, and 0.5%). Data are expressed as
mean ± S.E.M. (n=5). **P < 0.01 and ***P < 0.001 when compared to the
vehicle-treated group (One-way ANOVA followed by Bonferroni's test).
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030031 or silver sulfadiazine reduced dynamic mechanical allodynia
from 2 until 6 days after the thermal injury, with an inhibition of
89 ± 5% and 67 ± 11%, respectively on the 5th day after thermal
injury (Fig. 3B).
Also, it was observed the development of thermal allodynia from
1 day until 6 days after thermal injury (with mean values of 12.4 s for
the control group and 3.5 s for the group with the thermal injury
without treatment at 6 days after lesion; Fig. 4A). It was observed the
antinociceptive effect of HC-030031 or silver sulfadiazine from day 3 to
6, after injury (47 ± 6% and 57 ± 6% of inhibition, respectively, on
day 6 after thermal injury; Fig. 4A).
Furthermore, thermal injury caused spontaneous nociception from
day 1 until day 6 after injury (2.42 s for control group vs. 17.28 s for no
treated group, observed on day 4 after thermal injury; Fig. 4B). Also, it
was observed that treatment with HC-030031 reduced the spontaneous
pain induced by thermal injury on days 2, 4 (48 ± 9% inhibition), 5
and 6 after injury (Fig. 4B). Also, silver sulfadiazine presented anti-
nociceptive effect on day 4 (67 ± 8% inhibition), 5, and 6 after injury
(Fig. 4B). The topical treatment with the base cream (vehicle) did not
alter static, dynamic, thermal allodynia or spontaneous nociception
induced by thermal injury model (Figs. 3 and 4).
3.3. Base cream containing HC-030031 induced anti-inflammatory effects
in a thermal injury model
The animals that received the thermal injury and did not receive
treatment presented edema characterized by paw thickness increase,
when compared to the control group (no injury), with mean 5.5mm
and 0.42mm, respectively (6 days after the lesion; Fig. 5A). Topical
application of the base cream (vehicle) did not promote anti-
edematogenic effect. However, topical treatment with HC-030031 re-
duced the edema formation caused by thermal injury from day 1 until
Fig. 3. Time-course of the TRPA1 antagonist (HC-030031) topical treatment on
(A) static mechanical allodynia or (B) dynamic mechanical allodynia induced
by thermal injury in rats. Silver sulfadiazine 1% was used as positive control in
this model of inflammatory pain. The animals were divided into the following
groups: Control (no thermal injury induction), No treatment (thermal injury
without topical treatment, Vehicle (thermal injury and treated with base
cream), HC-030031 0.05% (thermal injury and treated with base cream con-
taining HC-030031), and Sulfadiazine 1% (thermal injury and treated with base
cream containing silver sulfadiazine). Nociception was measured before
(baseline values) and once a day from day 1 to 6 after thermal injury. Data are
expressed as mean ± S.E.M. (n=7). *P < 0.05; **P < 0.01, and
***P < 0.001 when compared to the no treatment or vehicle (base cream)
treated groups. #P < 0.001 when compared to control group (Two-way
ANOVA followed by Bonferroni's test).
Fig. 4. Time-course of the topical treatment using a TRPA1 antagonist (HC-
030031) on (A) thermal allodynia or (B) spontaneous nociception induced by
thermal injury in rats. Silver sulfadiazine 1% was used as positive control.
Nociception was measured before (baseline values) and once a day from day 1
to 6 after thermal injury. Data are expressed as mean ± S.E.M. (n=7).
*P < 0.05; **P < 0.01, and ***P < 0.001 when compared to the no treat-
ment or vehicle-treated groups. #P < 0.001 when compared to control group
(Two-way ANOVA followed by Bonferroni's test).
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day 6 after thermal injury with an inhibition of 46 ± 5% at day 6 after
thermal injury). Also, the application of silver sulfadiazine reduced
edema formation from 1 to 6 days after thermal injury with an
inhibition of 46 ± 5% at 6 days after thermal injury (Fig. 5A).
Also, we evaluated the MPO and NAGase activities in the hind paw
skin tissue at 6 days after thermal injury. The thermal injury increased
the MPO and NAGase activities when compared with the control group
(Fig. 5B and C). The base cream (vehicle) treatment did not reduce the
MPO and NAGase activities. However, HC-030031 or silver sulfadiazine
decreased these inflammatory parameters with an inhibition of
68 ± 10 and 73 ± 2% for MPO activity, and 79 ± 5 and 80 ± 2%
for NAGase activity, respectively (Fig. 5B and C).
Furthermore, we performed the histological analysis to confirm the
leukocyte infiltration at the paw tissue, at 6 days after thermal injury.
Here, we observed that thermal injury increased the leukocyte in-
filtration at the paw skin tissue when compared to the control group
(Fig. 6). The number of infiltrated inflammatory cells was significantly
lower in the groups treated with HC-030031 or silver sulfadiazine, with
an inhibition of 76 ± 2% and 82 ± 4%, respectively. However, the
topical treatment with the base cream (vehicle) did not decrease the
number of infiltrated inflammatory cells (Fig. 6).
3.4. H2O2 content, NADPH oxidase, and SOD activity were reduced by HC-
030031 treatment in a thermal injury model
The thermal injury increased the H2O2 content, and the NADPH
oxidase and SOD activities when compared to the control group
(Fig. 7A, B, and C). Moreover, the groups treated with HC-030031 or
silver sulfadiazine reduced all oxidative parameters evaluated, with an
inhibition of 71 ± 6 and 69 ± 10% to H2O2 levels; 60 ± 7 and
66 ± 10% to NADPH oxidase activity and 68 ± 7 and 67 ± 7% to
SOD activity, respectively (Fig. 7A, B, and C). However, topical treat-
ment with the base cream did not reduce these oxidative stress para-
meters after thermal injury (Fig. 7A, B, and C).
4. Discussion
The pain observed in patients with a burn is often disabling and can
lead to different psychological conditions even after recovery (Xie et al.,
2012). Until now, there are no drugs that effectively act in all sorts of
pain, because these treatments may be related to adverse effects de-
velopment (McIntyre et al., 2016). Thus, it is necessary to search for
novel mechanisms that could be associated with pain caused by thermal
injuries, and which may aid in the development of the new treatments
(Chang and Waxman, 2010; Fowler et al., 2014; Silva et al., 2014; Ueda
et al., 2014). Here, we assessed the topical analgesic effect of a base
cream containing a TRPA1 antagonist. The topical treatment using a
TRPA1 antagonist exerted antinociceptive and anti-inflammatory ef-
fects, and it shows the relevant role of the peripheral TRPA1 channel in
this model of inflammatory pain.
In this sense, several animal models of thermal lesion have been
developed to evaluate the analgesic and anti-inflammatory effects of
compounds in mice and rats (McIntyre et al., 2016). The pain model
induced by high-temperature water burn has been used in previous
studies, and it has an interesting approach because no extensive lesion
is generated in the animal by this model. Besides, this thermal injury
model presents an inflammatory action limited to the affected area
(Jeschke et al., 2009), leading to nociception in the hind paw, an easily
accessible hairless site to evaluate the nociception parameters (Barrot,
2012). So far, no studies have been done with a topical formulation
containing TRPA-specific antagonists such as HC-030031. In previous
studies, TRPA1 antagonists were locally injected in models of neuro-
pathic and inflammatory pain, showing antinociceptive activity
without induction of adverse effects (Pinheiro et al., 2015; Trevisan
et al., 2016, 2014). So, in the current study, the acute pain model in-
duced by administration of AITC (a TRPA1 agonist) (Trevisan et al.,
2014) was chosen to determine the possible antinociceptive effect of
topical application of a base cream containing HC-030031.
Moreover, we may suggest that HC-030031 incorporated in the base
Fig. 5. (A) Time-course of the topical treatment with a base cream containing
HC-030031 (0.05%) on paw edema induced by thermal injury in rats. Silver
sulfadiazine 1% was used as positive control. Paw edema was measured before
(baseline values) and once a day from day 1 to 6 after thermal injury. Data are
expressed as mean ± S.E.M. (n= 7; Two-way ANOVA followed by
Bonferroni's test). (B) Myeloperoxidase or (C) N-acetyl-β-D-glucosaminidase
activities observed in the skin hind paw tissue at 6 days after the thermal injury
or control groups. Data are expressed as mean ± S.E.M. (n= 5–7). *P < 0.05
when compared to the no treatment or vehicle-treated groups. #P < 0.001
when compared to control group (One-way ANOVA followed by Bonferroni's
test).
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cream formulation was responsible for the antinociceptive effect ob-
served after burn injury because the topical treatment with only base
cream (vehicle) did not reduce the nociceptive parameters evaluated
when compared with control group. TRPA1 is not usually described as a
mechanosensitive ion channel, but the injection of TRPA1 agonists may
cause mechanical allodynia, which was reduced by TRPA1 antagonists
(Griggs et al., 2017; Trevisan et al., 2013; Tsagareli et al., 2010).
Moreover, several reports showed that TRPA1 antagonism might reduce
mechanical allodynia in models of inflammatory and neuropathic pain
(Andrade et al., 2012; Nassini et al., 2014).
A significant number of agents found in the inflammation site could
sensitize TRPV1 and TRPA1 channels; then it is essential to reduce this
process to observe an antinociceptive effect (Sousa-Valente et al.,
2014). The TRPA1 receptor is normally found in sensory neurons that
express TRPV1, a noxious heat sensor, so the antagonism of the TRPA1
by reducing inflammation could also decrease TRPV1 sensitization,
thus reducing heat hyperalgesia (Gouin et al., 2017). Moreover, the
injection of TRPA1 agonists may cause heat hypersensitivity, which was
blocked by TRPA1 antagonists (Griggs et al., 2017; Tsagareli et al.,
2010), and TRPA1 agonists also induced heat hypersensitivity in hu-
mans (Andersen et al., 2017; Namer et al., 2005). Moreover, it has been
described that TRPV1, TRPM3 and TRPA1 function together with the
detection of acute noxious heat (Vandewauw et al., 2018). Thus, pos-
sible in the model used in this study the TRPA1 antagonism has con-
tributed to reducing TRPV1 sensitization by HC-030031 anti-in-
flammatory effect so that HC-030031 can decrease heat allodynia.
However, it is relevant to note that other pain mechanisms were already
described to be involved in burn pain, such as activation of TRPV1 and
P2X2/3 receptors. Also, as the composition of burn injury is complex the
attempt to find a leading compound produced in this fluid is compli-
cated, but it is interesting to search for a group of receptors that could
be activated at the site of injury (Laycock et al., 2013). The TRPA1 as
indicated by our results could also be included as a target to reduce pain
after burn injury, but it is difficult to sustain that is the sole mechanism
in this pain pathology. Thus, we could hypothesize that as TRPA1 is a
sensor for a myriad of harmful compounds produced after burning this
could be highly activated causing calcium influx and neurogenic in-
flammation, then initially TRPA1 gating could create and maintain
nociceptor sensitization.
Also, the TRPA1 antagonist ability in reducing spontaneous noci-
ception was reported previously in a craniofacial muscle pain model
(Asgar et al., 2015). A similar antinociceptive result had already been
described for silver sulfadiazine 1% cream in the same model in rats
(Silva et al., 2013). Silver sulfadiazine also showed positive results in
these tests, which agrees with its analgesic effect described in the clinic
(Nasiri et al., 2016; Shahzad and Ahmed, 2013). Although many studies
demonstrated the adverse effects related to the silver sulfadiazine use,
this treatment still being indicated to reduce the burn lesions
(Andersson et al., 2008; Irimia et al., 2011; Labuz and Machelska,
2013). Systemic adverse effects such as renal toxicity and leukopenia
are also described, suggesting that the use of silver sulfadiazine would
not be indicated in long-term treatments (Andersson et al., 2008). Silver
sulfadiazine is a standard topic treatment for partial burn injuries, the
main reason to be used in the current study as a positive control
(Abboud et al., 2014; Atiyeh et al., 2007; Marx and Barillo, 2014). In-
deed, silver sulfadiazine is primarily used in burn injuries to induce
antimicrobial effect, but it was already described that this compound
could also reduce inflammation and nociception in animal models of
thermal injury (Abboud et al., 2014; Nadworny et al., 2008; Piana et al.,
2013; Silva et al., 2014).
Therefore, considering that the thermal injury model also causes
continuous inflammation in the affected tissue, we also evaluated
Fig. 6. Effect of a topically applied base cream (200mg/paw) containing HC-030031 (0.05%) or silver sulfadiazine on histological changes (A–E) (hematoxylin-eosin
200×) and the number of inflammatory cells (polymorphonuclear leukocytes) per field (F) on rat's paw submitted to the thermal injury. Each bar represents the
mean ± S.E.M. (n=6). The arrows indicate the presence of inflammatory cells in the paw tissue. The following figure captions represent: (A) Control; (B) No
treatment; (C) Vehicle; (D) Sulfadiazine 1%; and (E) HC-030031 0.05%. The graphic symbols denote the significance levels when compared with the Control and no
treatment groups. ***P < 0.001 when compared with the No treatment group. ###P < 0.001 when compared with control group (One-way ANOVA followed by
Bonferroni's test). Scale bar, 100 μm.
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inflammatory parameters, such as paw edema (Silva et al., 2013).
Edema can be induced by several factors including vasodilation, ex-
travascular osmotic activity, and augmented microvascular perme-
ability, which frequently accompanies inflammation after burn
(Arturson, 2000; Rowan et al., 2015). However, excessive or prolonged
edema and inflammation prejudice wound healing (Edgar et al., 2011;
Sommer et al., 2013). In this sense, anti-inflammatory drugs also could
aid in the pain and edema treatment (Walls et al., 2017). However, the
long-term use of non-steroidal analgesics/anti-inflammatories or even
corticosteroids implies not only loss of efficacy, but also adverse effects
development, which limits their use (Irimia et al., 2011; Monteith and
Goadsby, 2011; Paemeleire et al., 2006; Stovner et al., 2009).
Moreover, other burn treatments, such as morphine or gabapentin, are
used because they present analgesic properties but lack of anti-in-
flammatory effects (Gamst-Jensen et al., 2014; McIntyre et al., 2016;
Richardson and Mustard, 2009; Singer and Dagum, 2008). The HC-
030031 antiedematogenic effect was previously reported through oral
or intraplantar administration (Trevisan et al., 2014). It was already
described that TRPA1 activation causes the release of calcitonin gene-
related peptide (CGRP) or vascular endothelial growth factor (VEGF),
and these mediators are involved in the increase of vascular perme-
ability observed in burn damage (Gherardini et al., 2009; Siney and
Brain, 1996; Infanger et al., 2004; Volpi et al., 2011).
After thermal lesion, neutrophils and macrophages infiltration to
the lesion site is involved not only in the initiation and resolution steps
of the acute inflammation but also chronic inflammation (Evers et al.,
2010; Fullerton and Gilroy, 2016; Gamst-Jensen et al., 2014; Laycock
et al., 2013; McIntyre et al., 2016; de Oliveira et al., 2016). However,
an excessive inflammatory cell infiltration may contribute to the sen-
sitization of nociceptors due to the continuous inflammatory mediator's
production and release (Laycock et al., 2013; McIntyre et al., 2016;
Summer et al., 2007). Here, we demonstrated that the thermal lesion
model produced an inflammatory cells infiltration to the lesion site.
Such findings were shown by the increase of enzymes markers of the
neutrophil and macrophages infiltration (myeloperoxidase and NA-
Gase, respectively), and confirmed by the histological sections of rats'
paw tissue, results which were previously described by Silva et al.
(2013). Previously, in models of acute inflammation, it was reported
that TRPA1 antagonists could reduce the inflammatory process (da
Costa et al., 2010; Eid et al., 2008; Horváth et al., 2016; McGaraughty
et al., 2010; Petrus et al., 2007).
The TRPA1 is expressed in sensory terminals located in the dermis
and epidermis, and its activation promotes the calcium influx induced
by signs of damage, such as the excessive production of oxidizing
substances, as hydrogen peroxide and 4-hydroxynonenal (4-HNE).
Hydrogen peroxide has been linked to the development of different
painful conditions in animal models of acute pain, such as in gout
(Moilanen et al., 2015; Trevisan et al., 2013, 2014), inflammatory ar-
thritis (Keeble et al., 2009; Moilanen et al., 2015), or neuropathic pain
(Trevisan et al., 2016). Thus, many studies have demonstrated that the
hydrogen peroxide production by tissue-resident cells (i.e., synovio-
cytes), macrophages and neutrophils, could favor the sensitization of
nociceptors via TRPA1 activation (Moilanen et al., 2015; Trevisan et al.,
2016, 2014). Previous studies reported that thermal burn might in-
crease the reactive species production, which could contribute to the
tissue damage (Bhatia et al., 2016; Hoşnuter et al., 2004; Parihar et al.,
2008; Silveira et al., 2016; Tanaka et al., 1999). In this sense, anti-
oxidants are designed to reduce production and to capture reactive
species that promote tissue lesion (Wasiak et al., 2013). Besides, these
treatments may be useful in the burn-induced pain reduction, as well as,
in patients with systemic responses, allowing a longer time of patient
survival and helping the necrotic tissue reduction in the wound (Lee
et al., 2011; Rock et al., 1997). Thus, the TRPA1 channel could be ac-
tivated by these oxidant compounds which would cause inflammation
and nociception. Therefore, our findings showed altered oxidative
status in the animals after thermal injury when compared to the con-
trols. These findings may be associated with the anti-inflammatory ef-
fect of HC-030031 and silver sulfadiazine formulations because the
reduced infiltration of inflammatory cells consequently decreases the
reactive species production by these cells.
The mechanisms of post-burn pain are still not completely under-
stood, but the thermal burn injury frequently induced pain by the in-
flammatory processes generated after the initial trauma. Moreover, this
type of inflammatory pain is often associated to the presence of in-
filtrated leukocytes in the damaged skin and the constant release and
production of distinct inflammatory and oxidant mediators (McIntyre
et al., 2016; Laycock et al., 2013). The established capacity of TRPA1 to
sense oxidative stress (Mori et al., 2016; Nassini et al., 2014; Andersson
Fig. 7. Effects of the base cream containing HC-030031 (0.05%) on (A) hy-
drogen peroxide concentration, or (B) NADPH and (C) SOD activities in a model
of thermal injury in rats. Silver sulfadiazine 1% was used as positive control.
Data are expressed as mean ± S.E.M. (n=5–7). *P < 0.05 when compared to
the no treatment or vehicle-treated groups. #P < 0.001 when compared to
control group (One-way ANOVA followed by Bonferroni's test).
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et al., 2008; Trevisani et al., 2007), led to the hypothesis that in-
flammatory pain is sustained by the oxidative burden generated by
infiltrating leukocytes that continuously target TRPA1 in nerve fibers,
causing nociception and inflammation. Thus, the blockage of this re-
ceptor could reduce calcium influx mediated by TRPA1 and the con-
sequent neurogenic inflammation promoted by this receptor. It was
already showed that the antagonism of the TRPA1 receptor could re-
duce inflammation and nociception in different models of inflammatory
pain (Andrade et al., 2012; Nassini et al., 2014), thus this receptor has
emerged as a potential drug target as it functions as a sensor for tissue
damage and inflammation (Viana, 2016). In addition, some studies
showed that TRPA1 activation by oxidant compounds may cause cal-
cium influx inducing the activation of NADPH oxidase and production
of intracellular reactive compounds that induce nuclear factor-κB (NF-
κB) or/and mitogen-activated protein kinases (MAPKs) signaling (Lin
et al., 2015; Lee et al., 2016). Then, this process could regulate the
expression of inflammatory genes in the injured tissues, once we an-
tagonize the TRPA1, the enhancement in NADPH oxidase activity and
the increase in intracellular reactive oxygen species production are
inhibited, which may reduce the further activation of NF-kB. Also, it
was previously described that TRPA1 gene expression is induced via
NF-κB signaling (Hatano et al., 2012). Also, it was studied that TRPA1
gating induces activation of mitogen-activated protein kinase (MAPK)
(Kondo et al., 2013; Volpi et al., 2011; Lin et al., 2015). In this frame,
therefore, it is possible that the antagonism caused a reduction of cal-
cium influx through TRPA1 channels, which in turn prevent NF-kB/
MAPK activation during inflammatory responses.
Also, the afterburn neuropathic pain occurrence, accompanied or
not by pruritus, is usually controlled with the use of non-opioid drugs
such as gabapentin and amitriptyline, and it is a form of opioid resistant
pain (McIntyre et al., 2016). However, these treatments are not effec-
tive in all patients and often cause adverse effects, which makes topical
treatment an interesting alternative mainly related to pain observed in
small- and medium-severity burns (Burgess and Williams, 2010; Evers
et al., 2010; Labuz and Machelska, 2013). In this view, the use of a
TRPA1 antagonism by the topical application could be combined with a
systemic medication such as an anticonvulsant drug. Moreover, TRPA1
has been pointed as a mediator of itch in distinct models (Kittaka and
Tominaga, 2017), so combining a TRPA1 antagonism by topical ap-
plication with a systemic medication, could be useful to reduce in-
flammation and possible pruritus in burn patients.
In conclusion, this study presents results indicating the effect of
TRPA1 antagonists on nociception and inflammation control in a
thermal lesion model. Therefore, from the results currently obtained,
the TRPA1 channel presents as a relevant and promising source for the
development of new analgesics, which could be used for pain treat-
ment, specially developed after thermal injury.
Acknowledgments
This study was supported by National Research Council of Brazil
(CNPq; #422376/2016-7). C.T.D.A., S.D.T.D.P., A.S.A., C.C., G.B.S. are
recipients of fellowships from Coordination of Improvement of Higher
Education Personnel (CAPES).
Disclosure
The authors declare no conflict of interest. None of the authors have
received compensation for professional services in any of the previous
years or anticipate receiving such compensation in the near future.
Ethical approval
All applicable international, national, and/or institutional guide-
lines for the care and use of animals were followed.
References
Abboud, E.C., Legare, T.B., Settle, J.C., Boubekri, A.M., Barillo, D.J., Marcet, J.E.,
Sanchez, J.E., 2014. Do silver-based wound dressings reduce pain? A prospective
study and review of the literature. Burns 40, S40–S47. https://doi.org/10.1016/j.
burns.2014.09.012.
Andersen, H.H., Lo Vecchio, S., Gazerani, P., Arendt-Nielsen, L., 2017. Dose-response
study of topical allyl isothiocyanate (mustard oil) as a human surrogate model of
pain, hyperalgesia, and neurogenic inflammation. Pain 158, 1723–1732. https://doi.
org/10.1097/j.pain.0000000000000979.
Andersson, D.A., Gentry, C., Moss, S., Bevan, S., 2008. Transient receptor potential A1 is a
sensory receptor for multiple products of oxidative stress. J. Neurosci. 28,
2485–2494. https://doi.org/10.1523/JNEUROSCI.5369-07.2008.
Andrade, E.L., Meotti, F.C., Calixto, J.B., 2012. TRPA1 antagonists as potential analgesic
drugs. Pharmacol. Ther. 133, 189–204. https://doi.org/10.1016/j.pharmthera.2011.
10.008.
Arturson, G., 2000. Forty years in burns research - the postburn inflammatory response.
Burns 26, 599–604. https://doi.org/10.1016/S0305-4179(00)00069-3.
Asgar, J., Zhang, Y., Saloman, J.L., Wang, S., Chung, M.-K., Ro, J.Y., 2015. The role of
TRPA1 in muscle pain and mechanical hypersensitivity under inflammatory condi-
tions in rats. Neuroscience 310, 206–215. https://doi.org/10.1016/j.neuroscience.
2015.09.042.
Atiyeh, B.S., Costagliola, M., Hayek, S.N., Dibo, S.A., 2007. Effect of silver on burn wound
infection control and healing: review of the literature. Burns 33, 139–148. https://
doi.org/10.1016/j.burns.2006.06.010.
Bang, S., Hwang, S.W., 2009. Polymodal ligand sensitivity of TRPA1 and its modes of
interactions. J. Gen. Physiol. 133, 257–262. https://doi.org/10.1085/jgp.
200810138.
Bannister, J.V., Calabrese, L., 1987. Assays for superoxide dismutase. In: Methods of
Biochemical Analysis. John Wiley & Sons, Inc., pp. 279–312.
Baraldi, P.G., Preti, D., Materazzi, S., Geppetti, P., 2010. Transient receptor potential
Ankyrin 1 (TRPA1) channel as emerging target for novel analgesics and anti-in-
flammatory agents. J. Med. Chem. 53, 5085–5107. https://doi.org/10.1021/
jm100062h.
Barrot, M., 2012. Tests and models of nociception and pain in rodents. Neuroscience 211,
39–50. https://doi.org/10.1016/j.neuroscience.2011.12.041.
Bhatia, N., Kaur, G., Soni, V., Kataria, J., Dhawan, R.K., 2016. Evaluation of the wound
healing potential of isoquercetin-based cream on scald burn injury in rats. Burn
Trauma 4, 7. https://doi.org/10.1186/s41038-016-0032-1.
Bishop, T., Hewson, D.W., Yip, P.K., Fahey, M.S., Dawbarn, D., Young, A.R., McMahon,
S.B., 2007. Characterisation of ultraviolet-B-induced inflammation as a model of
hyperalgesia in the rat. Pain 131, 70–82. https://doi.org/10.1016/j.pain.2006.12.
014.
Bradford, M.M., 1976. A rapid and sensitive method for the quantitation of microgram
quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72,
248–254. https://doi.org/10.1016/0003-2697(76)90527-3.
Burgess, G., Williams, D., 2010. The discovery and development of analgesics: new me-
chanisms, new modalities. J. Clin. Invest. 120, 3753–3759. https://doi.org/10.1172/
JCI43195.
Chang, Y.-W., Waxman, S.G., 2010. Minocycline attenuates mechanical allodynia and
central sensitization following peripheral second-degree burn injury. J. Pain 11,
1146–1154. https://doi.org/10.1016/j.jpain.2010.02.010.
Chaplan, S.R., Bach, F.W., Pogrel, J.W., Chung, J.M., Yaksh, T.L., 1994. Quantitative
assessment of tactile allodynia in the rat paw. J. Neurosci. Methods 53, 55–63.
https://doi.org/10.1016/0165-0270(94)90144-9.
Chibli, L.A., Rodrigues, K.C.M., Gasparetto, C.M., Pinto, N.C.C., Fabri, R.L., Scio, E.,
Alves, M.S., Del-Vechio-Vieira, G., Sousa, O.V., 2014. Anti-inflammatory effects of
Bryophyllum pinnatum (Lam.) Oken ethanol extract in acute and chronic cutaneous
inflammation. J. Ethnopharmacol. 154, 330–338. https://doi.org/10.1016/j.jep.
2014.03.035.
Cuttle, L., Pearn, J., McMillan, J.R., Kimble, R.M., 2009. A review of first aid treatments
for burn injuries. Burns 35, 768–775. https://doi.org/10.1016/j.burns.2008.10.011.
da Costa, D.S.M., Meotti, F.C., Andrade, E.L., Leal, P.C., Motta, E.M., Calixto, J.B., 2010.
The involvement of the transient receptor potential A1 (TRPA1) in the maintenance
of mechanical and cold hyperalgesia in persistent inflammation. Pain 148, 431–437.
https://doi.org/10.1016/j.pain.2009.12.002.
de Oliveira, S., Rosowski, E.E., Huttenlocher, A., 2016. Neutrophil migration in infection
and wound repair: going forward in reverse. Nat. Rev. Immunol. 16, 378–391.
https://doi.org/10.1038/nri.2016.49.
Dixon, W.J., 1980. Efficient analysis of experimental observations. Annu. Rev. Pharmacol.
Toxicol. 20, 441–462. https://doi.org/10.1146/annurev.pa.20.040180.002301.
Edgar, D.W., Fish, J.S., Gomez, M., Wood, F.M., 2011. Local and systemic treatments for
acute edema after burn injury: a systematic review of the literature. J. Burn Care Res.
32, 334–347. https://doi.org/10.1097/BCR.0b013e31820ab019.
Eid, S.R., Crown, E.D., Moore, E.L., Liang, H.A., Choong, K.-C., Dima, S., Henze, D.A.,
Kane, S.A., Urban, M.O., 2008. HC-030031, a TRPA1 selective antagonist, attenuates
inflammatory- and neuropathy-induced mechanical hypersensitivity. Mol. Pain 4,
1744–1748. https://doi.org/10.1186/1744-8069-4-48.
Evers, L.H., Bhavsar, D., Mailänder, P., 2010. The biology of burn injury. Exp. Dermatol.
19, 777–783. https://doi.org/10.1111/j.1600-0625.2010.01105.x.
Fowler, M., Clifford, J.L., Garza, T.H., Slater, T.M., Arizpe, H.M., Novak, J., Petz, L.N.,
Loyd, D.R., 2014. A rat model of full-thickness thermal injury characterized by
thermal hyperalgesia, mechanical allodynia, pronociceptive peptide release and
tramadol analgesia. Burns 40, 759–771. https://doi.org/10.1016/j.burns.2013.10.
011.
Antoniazzi et al. European Journal of Pharmaceutical Sciences 125 (2018) 28–38
36
Fullerton, J.N., Gilroy, D.W., 2016. Resolution of inflammation: a new therapeutic
frontier. Nat. Rev. Drug Discov. 15, 551–567. https://doi.org/10.1038/nrd.2016.39.
Gamst-Jensen, H., Vedel, P.N., Lindberg-Larsen, V.O., Egerod, I., 2014. Acute pain
management in burn patients: appraisal and thematic analysis of four clinical
guidelines. Burns 40, 1463–1469. https://doi.org/10.1016/j.burns.2014.08.020.
Gao, Y., Xu, C., Yu, K., Li, G., Wan, F., Liu, S., Lin, J., Liu, H., Zhang, J., Li, X., Liang, S.,
2010. Effect of tetramethylpyrazine on DRG neuron P2X3 receptor involved in
transmitting pain after burn. Burns 36, 127–134. https://doi.org/10.1016/j.burns.
2009.04.032.
Geppetti, P., Nassini, R., Materazzi, S., Benemei, S., 2008. The concept of neurogenic
inflammation. BJU Int. 101, 2–6. https://doi.org/10.1111/j.1464-410X.2008.
07493.x.
Gherardini, G., Curinga, G., Colella, G., Freda, N., Rauso, R., 2009. Calcitonin gene-re-
lated peptide and termal injury: review of literature. Eplasty 9, e30.
Gouin, O., L'Herondelle, K., Lebonvallet, N., Le Gall-Ianotto, C., Sakka, M., Buhé, V., Plée-
Gautier, E., Carré, J.-L., Lefeuvre, L., Misery, L., Le Garrec, R., 2017. TRPV1 and
TRPA1 in cutaneous neurogenic and chronic inflammation: pro-inflammatory re-
sponse induced by their activation and their sensitization. Protein Cell. 8, 644–661.
https://doi.org/10.1007/s13238-017-0395-5.
Green, D.P., Ruparel, S., Gao, X., Ruparel, N., Patil, M., Akopian, A., Hargreaves, K.M.,
2016. Central activation of TRPV1 and TRPA1 by novel endogenous agonists con-
tributes to mechanical and thermal allodynia after burn injury. Mol. Pain 12,
174480691666172. https://doi.org/10.1177/1744806916661725.
Griggs, R.B., Laird, D.E., Donahue, R.R., Fu, W., Taylor, B.K., 2017. Methylglyoxal re-
quires AC1 and TRPA1 to produce pain and spinal neuron activation. Front. Neurosci.
11. https://doi.org/10.3389/fnins.2017.00679.
Hatano, N., Itoh, Y., Suzuki, H., Muraki, Y., Hayashi, H., Onozaki, K., Wood, I.C., Beech,
D.J., Muraki, K., 2012. Hypoxia-inducible factor-1α (HIF1α) switches on transient
receptor potential ankyrin repeat 1 (TRPA1) gene expression via a hypoxia response
element-like motif to modulate cytokine release. J. Biol. Chem. 287, 31962–31972.
https://doi.org/10.1074/jbc.M112.361139.
Hinman, R.S., Heywood, S.E., Day, A.R., 2007. Aquatic physical therapy for hip and knee
osteoarthritis: results of a single-blind randomized controlled trial. Phys. Ther. 87,
32–43. https://doi.org/10.2522/ptj.20060006.
Horváth, Á., Tékus, V., Boros, M., Pozsgai, G., Botz, B., Borbély, É., Szolcsányi, J., Pintér,
E., Helyes, Z., 2016. Transient receptor potential ankyrin 1 (TRPA1) receptor is in-
volved in chronic arthritis: in vivo study using TRPA1-deficient mice. Arthritis Res.
Ther. 18, 6. https://doi.org/10.1186/s13075-015-0904-y.
Hoşnuter, M., Gürel, A., Babucçu, O., Armutcu, F., Kargi, E., Işikdemir, A., 2004. The
effect of CAPE on lipid peroxidation and nitric oxide levels in the plasma of rats
following thermal injury. Burns 30, 121–125. https://doi.org/10.1016/j.burns.2003.
09.022.
Infanger, M., Schmidt, O., Kossmehl, P., Grad, S., Ertel, W., Grimm, D., 2004. Vascular
endothelial growth factor serum levels is strongly enhanced after burn injury and
correlated with local and general tissue edema. Burns 30, 305–311.
Irimia, P., Palma, J.-A., Fernandez-Torron, R., Martinez-Vila, E., 2011. Refractory mi-
graine in a headache clinic population. BMC Neurol. 11, 94. https://doi.org/10.
1186/1471-2377-11-94.
Jaggi, A.S., Singh, N., 2011. Exploring the potential of telmisartan in chronic constriction
injury-induced neuropathic pain in rats. Eur. J. Pharmacol. 667, 215–221. https://
doi.org/10.1016/j.ejphar.2011.06.017.
James, D.L., Jowza, M., 2017. Principles of burn pain management. Clin. Plast. Surg. 44,
737–747. https://doi.org/10.1016/j.cps.2017.05.005.
Jeschke, M.G., Gauglitz, G.G., Song, J., Kulp, G.A., Finnerty, C.C., Cox, R.A., Barral, J.M.,
Herndon, D.N., Boehning, D., 2009. Calcium and ER stress mediate hepatic apoptosis
after burn injury. J. Cell. Mol. Med. 13, 1857–1865. https://doi.org/10.1111/j.1582-
4934.2009.00644.x.
Keeble, J.E., Bodkin, J.V., Liang, L., Wodarski, R., Davies, M., Fernandes, E.S., Coelho, C.
de F., Russell, F., Graepel, R., Muscara, M.N., Malcangio, M., Brain, S.D., 2009.
Hydrogen peroxide is a novel mediator of inflammatory hyperalgesia, acting via
transient receptor potential vanilloid 1-dependent and independent mechanisms.
Pain 141, 135–142. https://doi.org/10.1016/j.pain.2008.10.025.
Kittaka, H., Tominaga, M., 2017. The molecular and cellular mechanisms of itch and the
involvement of TRP channels in the peripheral sensory nervous system and skin.
Allergol. Int. 66, 22–30.
Klafke, J.Z., da Silva, M.A., Rossato, M.F., de Prá, S.D.T., Rigo, F.K., Walker, C.I.B., Bochi,
G.V., Moresco, R.N., Ferreira, J., Trevisan, G., 2016. Acute and chronic nociceptive
phases observed in a rat hind paw ischemia/reperfusion model depend on different
mechanisms. Pflugers Arch. - Eur. J. Physiol. 468, 229–241. https://doi.org/10.
1007/s00424-015-1746-9.
Kondo, T., Sakurai, J., Miwa, H., Noguchi, K., 2013. Activation of p38 MAPK through
transient receptor potential A1 in a rat model of gastric distension-induced visceral
pain. Neuroreport 24, 68–72. https://doi.org/10.1097/WNR.0b013e32835c7df2.
Labuz, D., Machelska, H., 2013. Stronger antinociceptive efficacy of opioids at the injured
nerve trunk than at its peripheral terminals in neuropathic pain. J. Pharmacol. Exp.
Ther. 346, 535–544. https://doi.org/10.1124/jpet.113.205344.
Laycock, H., Valente, J., Bantel, C., Nagy, I., 2013. Peripheral mechanisms of burn injury-
associated pain. Eur. J. Pharmacol. 716, 169–178. https://doi.org/10.1016/j.ejphar.
2013.01.071.
Lee, H., Kaneki, M., Andreas, J., Tompkins, R.G., Martyn, J.A.J., 2011. Novel mi-
tochondria-targeted antioxidant peptide ameliorates burn-induced apoptosis and
endoplasmic reticulum stress in the skeletal muscle of mice. Shock 36, 580–585.
https://doi.org/10.1097/SHK.0b013e3182366872.
Lee, E.G., Mickle-Kawar, B.M., Gallucci, R.M., 2013. IL-6 deficiency exacerbates skin
inflammation in a murine model of irritant dermatitis. J. Immunotoxicol. 10,
192–200. https://doi.org/10.3109/1547691X.2012.707700.
Lee, K.I., Lee, H.T., Lin, H.C., Tsay, H.J., Tsai, F.C., Shyue, S.K., Lee, T.S., 2016. Role of
transient receptor potential ankyrin 1 channels in Alzheimer's disease. J.
Neuroinflammation 13, 92. https://doi.org/10.1186/s12974-016-0557-z.
Levine, J.D., Alessandri-Haber, N., 2007. TRP channels: targets for the relief of pain.
Biochim. Biophys. Acta Mol. basis Dis. 1772, 989–1003. https://doi.org/10.1016/j.
bbadis.2007.01.008.
Lin, A.H., Liu, M.H., Ko, H.K., Perng, D.W., Lee, T.S., Kou, Y.R., 2015. Lung epithelial
TRPA1 transduces the extracellular ROS into transcriptional regulation of lung in-
flammation induced by cigarette smoke: the role of Influxed Ca2+. Mediat. Inflamm.
2015, 148367. https://doi.org/10.1155/2015/148367.
Marx, D.E., Barillo, D.J., 2014. Silver in medicine: the basic science. Burns 40, S9–S18.
https://doi.org/10.1016/j.burns.2014.09.010.
McGaraughty, S., Chu, K.L., Perner, R.J., Didomenico, S., Kort, M.E., Kym, P.R., 2010.
TRPA1 modulation of spontaneous and mechanically evoked firing of spinal neurons
in uninjured, osteoarthritic, and inflamed rats. Mol. Pain 6https://doi.org/10.1186/
1744-8069-6-14. (1744-8069-6–14).
McGrath, J.C., Lilley, E., 2015. Implementing guidelines on reporting research using
animals (ARRIVE etc.): new requirements for publication in BJP. Br. J. Pharmacol.
172, 3189–3193. https://doi.org/10.1111/bph.12955.
McIntyre, M.K., Clifford, J.L., Maani, C.V., Burmeister, D.M., 2016. Progress of clinical
practice on the management of burn-associated pain: lessons from animal models.
Burns 42, 1161–1172. https://doi.org/10.1016/j.burns.2016.01.023.
Moilanen, L.J., Hämäläinen, M., Lehtimäki, L., Nieminen, R.M., Moilanen, E., 2015. Urate
crystal induced inflammation and joint pain are reduced in transient receptor po-
tential Ankyrin 1 deficient mice - potential role for transient receptor potential
Ankyrin 1 in gout. PLoS One 10, e0117770. https://doi.org/10.1371/journal.pone.
0117770.
Monstrey, S., Hoeksema, H., Verbelen, J., Pirayesh, A., Blondeel, P., 2008. Assessment of
burn depth and burn wound healing potential. Burns 34, 761–769. https://doi.org/
10.1016/j.burns.2008.01.009.
Monteith, T.S., Goadsby, P.J., 2011. Acute migraine therapy: new drugs and new ap-
proaches. Curr. Treat. Options Neurol. 13, 1–14. https://doi.org/10.1007/s11940-
010-0105-6.
Mori, Y., Takahashi, N., Polat, O.K., Kurokawa, T., Takeda, N., Inohue, M., 2016. Redox-
sensitive transient receptor potential channels in oxygen sensing and adaptation.
Pflugers Arch. 468, 85–97. https://doi.org/10.1007/s00424-015-1716-2.
Nadworny, P.L., Wang, J., Tredget, E.E., Burrell, R.E., 2008. Anti-inflammatory activity of
nanocrystalline silver in a porcine contact dermatitis model. Nanomed.:
Nanotechnol., Biol. Med. 4, 241–251. https://doi.org/10.1016/j.nano.2008.04.006.
Nakamura, Y., Murakami, A., Ohto, Y., Torikai, K., Tanaka, T., 1998. Suppression of
tumor promoter-induced oxidative stress and inflammatory responses in mouse skin
by a superoxide generation inhibitor 1′-Acetoxychavicol acetate. Cancer Res. 58,
4832–4839.
Namer, B., Seifert, F., Handwerker, H.O., Maihöfner, C., 2005. TRPA1 and TRPM8 acti-
vation in humans: effects of cinnamaldehyde and menthol. Neuroreport 16, 955–959.
https://doi.org/10.1097/00001756-200506210-00015.
Nasiri, E., Hosseinimehr, S.J., Zaghi Hosseinzadeh, A., Azadbakht, M., Akbari, J.,
Azadbakht, M., 2016. The effects of Arnebia euchroma ointment on second-degree
burn wounds: a randomized clinical trial. J. Ethnopharmacol. 189, 107–116. https://
doi.org/10.1016/j.jep.2016.05.029.
Nassini, R., Materazzi, S., Benemei, S., Geppetti, P., 2014. The TRPA1 channel in in-
flammatory and neuropathic pain and migraine. In: Nilius, B., Gudermann, T., Jahn,
R., Lill, R., Offermanns, S., Petersen, O.H. (Eds.), Reviews of Physiology,
Biochemistry and Pharmacology. Springer International Publishing, Cham, pp. 1–43.
Oliveira, S.M., Silva, C.R., Wentz, A.P., Paim, G.R., Correa, M.S., Bonacorso, H.G.,
Prudente, A.S., Otuki, M.F., Ferreira, J., 2014. Antinociceptive effect of 3-(4-fluor-
ophenyl)-5-trifluoromethyl-1H-1-tosylpyrazole. A celecoxib structural analog in
models of pathological pain. Pharmacol. Biochem. Behav. 124, 396–404. https://doi.
org/10.1016/j.pbb.2014.07.005.
Paemeleire, K., Crevits, L., Goadsby, P.J., Kaube, H., 2006. Practical management of
medication-overuse headache. Acta Neurol. Belg. 106, 43–51.
Parihar, A., Parihar, M.S., Milner, S., Bhat, S., 2008. Oxidative stress and anti-oxidative
mobilization in burn injury. Burns 34, 6–17. https://doi.org/10.1016/j.burns.2007.
04.009.
Petrus, M., Peier, A.M., Bandell, M., Hwang, S.W., Huynh, T., Olney, N., Jegla, T.,
Patapoutian, A., 2007. A role of TRPA1 in mechanical hyperalgesia is revealed by
pharmacological inhibition. Mol. Pain 3https://doi.org/10.1186/1744-8069-3-40.
1744-8069-3–40.
Piana, M., Silva, M.A., Trevisan, G., de Brum, T.F., Silva, C.R., Boligon, A.A., Oliveira,
S.M., Zadra, M., Hoffmeister, C., Rossato, M.F., Tonello, R., Laporta, L.V., de Freitas,
R.B., Belke, B.V., Jesus, R. da S., Ferreira, J., Athayde, M.L., 2013. Antiinflammatory
effects of Viola tricolor gel in a model of sunburn in rats and the gel stability study. J.
Ethnopharmacol. 150, 458–465. https://doi.org/10.1016/j.jep.2013.08.040.
Piccolo, N., Serra, M., Leonardi, D., Lima Jr., E., Novaes, F., Correa, M., Cunha, L.,
Amaral, C., Prestes, M., Cunha, S., Piccolo, M., 2008. Projeto Diretrizes –
Queimaduras: Diagnóstico e Tratamento Inicial, 1st ed. Sociedade Brasileira de
Cirurgia Plástica, Sao Paulo, Brazil.
Pinheiro, F.D.V., Villarinho, J.G., Silva, C.R., Oliveira, S.M., Pinheiro, K.D.V., Petri, D.,
Rossato, M.F., Guerra, G.P., Trevisan, G., Antonello Rubin, M., Geppetti, P., Ferreira,
J., André, E., 2015. The involvement of the TRPA1 receptor in a mouse model of
sympathetically maintained neuropathic pain. Eur. J. Pharmacol. 747, 105–113.
https://doi.org/10.1016/j.ejphar.2014.11.039.
Raisinghani, M., Zhong, L., Jeffry, J.A., Bishnoi, M., Pabbidi, R.M., Pimentel, F., Cao, D.-
S., Steven Evans, M., Premkumar, L.S., 2011. Activation characteristics of transient
receptor potential ankyrin 1 and its role in nociception. Am. J. Physiol. Physiol. 301,
C587–C600. https://doi.org/10.1152/ajpcell.00465.2010.
Antoniazzi et al. European Journal of Pharmaceutical Sciences 125 (2018) 28–38
37
Richardson, P., Mustard, L., 2009. The management of pain in the burns unit. Burns 35,
921–936. https://doi.org/10.1016/j.burns.2009.03.003.
Rock, C.L., Dechert, R.E., Khilnani, R., Parker, R.S., Rodriguez, J.L., 1997. Carotenoids
and antioxidant vitamins in patients after burn injury. J. Burn Care Rehabil. 18,
268–278. https://doi.org/10.1097/00004630-199705000-00018.
Rowan, M.P., Cancio, L.C., Elster, E.A., Burmeister, D.M., Rose, L.F., Natesan, S., Chan,
R.K., Christy, R.J., Chung, K.K., 2015. Burn wound healing and treatment: review and
advancements. Crit. Care 19, 243. https://doi.org/10.1186/s13054-015-0961-2.
Sawada, Y., Hosokawa, H., Matsumura, K., Kobayashi, S., 2008. Activation of transient
receptor potential ankyrin 1 by hydrogen peroxide. Eur. J. Neurosci. 27, 1131–1142.
https://doi.org/10.1111/j.1460-9568.2008.06093.x.
Serrano, C., Boloix-Tortosa, R., Gómez-Cía, T., Acha, B., 2015. Features identification for
automatic burn classification. Burns 41, 1883–1890. https://doi.org/10.1016/j.
burns.2015.05.011.
Shahzad, M.N., Ahmed, N., 2013. Effectiveness of Aloe Vera gel compared with 1% silver
sulphadiazine cream as burn wound dressing in second degree burns. J. Pak. Med.
Assoc. 63, 225–230.
Silva, M.A., Trevisan, G., Klafke, J.Z., Rossato, M.F., Walker, C.I.B., Oliveira, S.M., Silva,
C.R., Boligon, A.A., Flores, F.C., Silva, C.D.B., Athayde, M.L., Ferreira, J., 2013.
Antinociceptive and anti-inflammatory effects of Aloe saponaria Haw on thermal
injury in rats. J. Ethnopharmacol. 146, 393–401. https://doi.org/10.1016/j.jep.
2012.12.055.
Silva, M.A., Trevisan, G., Hoffmeister, C., Rossato, M.F., Boligon, A.A., Walker, C.I.B.,
Klafke, J.Z., Oliveira, S.M., Silva, C.R., Athayde, M.L., Ferreira, J., 2014. Anti-in-
flammatory and antioxidant effects of Aloe saponaria Haw in a model of UVB-induced
paw sunburn in rats. J. Photochem. Photobiol. B Biol. 133, 47–54. https://doi.org/
10.1016/j.jphotobiol.2014.02.019.
Silveira, P.C.L., Ferreira, K.B., da Rocha, F.R., Pieri, B.L.S., Pedroso, G.S., De Souza, C.T.,
Nesi, R.T., Pinho, R.A., 2016. Effect of low-power laser (LPL) and light-emitting diode
(LED) on inflammatory response in burn wound healing. Inflammation. https://doi.
org/10.1007/s10753-016-0371-x.
Siney, L., Brain, S.D., 1996. Involvment of sensory neuropeptides in the development of
plasma extravasation in rat dorsal skin following thermal injury. Br. J. Pharmacol.
117, 1065–1070.
Singer, A.J., Dagum, A.B., 2008. Current management of acute cutaneous wounds. N.
Engl. J. Med. 359, 1037–1046. https://doi.org/10.1056/NEJMra0707253.
Sommer, K., Sander, A.L., Albig, M., Weber, R., Henrich, D., Frank, J., et al., 2013.
Delayed wound repair in sepsis is associated with reduced local pro-inflammatory
cytokine expression. PLoS One 8. https://doi.org/10.1371/journal.pone.0073992.
Song, H.Y., Lee, J.A., Ju, S.M., Yoo, K., Won, M.H., Kwon, H., Eum, W.S., Jang, S.H., Choi,
S.Y., Park, J., 2008. Topical transduction of superoxide dismutase mediated by HIV-1
Tat protein transduction domain ameliorates 12-O-tetradecanoylphorbol-13-acetate
(TPA)-induced inflammation in mice. Biochem. Pharmacol. 75, 1348–1357. https://
doi.org/10.1016/j.bcp.2007.11.015.
Sousa-Valente, J., Andreou, A.P., Urban, L., Nagy, I., 2014. Transient receptor potential
ion channels in primary sensory neurons as targets for novel analgesics. Br. J.
Pharmacol. 171, 2508–2527. https://doi.org/10.1111/bph.12532.
Souza, H.R., de Azevedo, L.R., Possebon, L., Costa, S. de S., Iyomasa-Pilon, M.M., Oliani,
S.M., Girol, A.P., 2017. Heterogeneity of mast cells and expression of Annexin A1
protein in a second degree burn model with silver sulfadiazine treatment. PLoS One
12, e0173417. https://doi.org/10.1371/journal.pone.0173417.
Stovner, L.J., Tronvik, E., Hagen, K., 2009. New drugs for migraine. J. Headache Pain 10,
395–406. https://doi.org/10.1007/s10194-009-0156-9.
Summer, G.J., Puntillo, K.A., Miaskowski, C., Green, P.G., Levine, J.D., 2007. Burn injury
pain: the continuing challenge. J. Pain 8, 533–548. https://doi.org/10.1016/j.jpain.
2007.02.426.
Takahashi, K., Sato, J., Mizumura, K., 2003. Responses of C-fiber low threshold me-
chanoreceptors and nociceptors to cold were facilitated in rats persistently inflamed
and hypersensitive to cold. Neurosci. Res. 47, 409–419. https://doi.org/10.1016/j.
neures.2003.08.003.
Tanaka, H., Lund, T., Wiig, H., Reed, R.K., Yukioka, T., Matsuda, H., Shimazaki, S., 1999.
High dose vitamin C counteracts the negative interstitial fluid hydrostatic pressure
and early edema generation in thermally injured rats. Burns 25, 569–574. https://
doi.org/10.1016/S0305-4179(99)00073-X.
Taylor-Clark, T.E., Undem, B.J., 2010. Ozone activates airway nerves via the selective
stimulation of TRPA1 ion channels. J. Physiol. 588, 423–433. https://doi.org/10.
1113/jphysiol.2009.183301.
Treede, R.-D., Rief, W., Barke, A., Aziz, Q., Bennett, M.I., Benoliel, R., Cohen, M., Evers,
S., Finnerup, N.B., First, M.B., Giamberardino, M.A., Kaasa, S., Kosek, E.,
Lavand'homme, P., Nicholas, M., Perrot, S., Scholz, J., Schug, S., Smith, B.H.,
Svensson, P., Vlaeyen, J.W.S., Wang, S.-J., 2015. A classification of chronic pain for
ICD-11. Pain 156, 1. https://doi.org/10.1097/j.pain.0000000000000160.
Trevisan, G., Hoffmeister, C., Rossato, M.F., Oliveira, S.M., Silva, M.A., Ineu, R.P., Guerra,
G.P., Materazzi, S., Fusi, C., Nassini, R., Geppetti, P., Ferreira, J., 2013. Transient
receptor potential Ankyrin 1 receptor stimulation by hydrogen peroxide is critical to
trigger pain during monosodium urate-induced inflammation in rodents. Arthritis
Rheum. 65, 2984–2995. https://doi.org/10.1002/art.38112.
Trevisan, G., Hoffmeister, C., Rossato, M.F., Oliveira, S.M., Silva, M.A., Silva, C.R., Fusi,
C., Tonello, R., Minocci, D., Guerra, G.P., Materazzi, S., Nassini, R., Geppetti, P.,
Ferreira, J., 2014. TRPA1 receptor stimulation by hydrogen peroxide is critical to
trigger hyperalgesia and inflammation in a model of acute gout. Free Radic. Biol.
Med. 72, 200–209. https://doi.org/10.1016/j.freeradbiomed.2014.04.021.
Trevisan, G., Benemei, S., Materazzi, S., De Logu, F., De Siena, G., Fusi, C., Fortes, M.F.,
Coppi, E., Marone, I.M., Ferreira, J., Geppetti, P., Nassini, R., 2016. TRPA1 mediates
trigeminal neuropathic pain in mice downstream of monocytes/macrophages and
oxidative stress. Brain 139, 1361–1377. https://doi.org/10.1093/brain/aww038.
Trevisani, M., Siemens, J., Materazzi, S., Bautista, D.M., Nassini, R., Campi, B., Imamachi,
N., Andrè, E., Patacchini, R., Cottrell, G.S., Gatti, R., Basbaum, A.I., Bunnett, N.W.,
Julius, D., Geppetti, P., 2007. 4-Hydroxynonenal, an endogenous aldehyde, causes
pain and neurogenic inflammation through activation of the irritant receptor TRPA1.
Proc. Natl. Acad. Sci. U. S. A. 104, 13519–13524. https://doi.org/10.1073/pnas.
0705923104.
Tsagareli, M.G., Tsiklauri, N., Zanotto, K.L., Carstens, M.I., Klein, A.H., Sawyer, C.M.,
Gurtskaia, G., Abzianidze, E., Carstens, E., 2010. Behavioral evidence of thermal
hyperalgesia and mechanical allodynia induced by intradermal cinnamaldehyde in
rats. Neurosci. Lett. 473, 233–236. https://doi.org/10.1016/j.neulet.2010.02.056.
Ueda, M., Iwasaki, H., Wang, S., Murata, E., Poon, K.Y.T., Mao, J., Martyn, J.A.J., 2014.
Cannabinoid receptor type 1 antagonist, AM251, attenuates mechanical allodynia
and thermal hyperalgesia after burn injury. Anesthesiology 121, 1311–1319. https://
doi.org/10.1097/ALN.0000000000000422.
Vandewauw, I., De Clercq, K., Mulier, M., Held, K., Pinto, S., Van Ranst, N., Segal, A.,
Voet, T., Vennekens, R., Zimmermann, K., Vriens, J., Voets, T., 2018. A TRP channel
trio mediates acute noxious heat sensing. Nature 555, 662–666. https://doi.org/10.
1038/nature26137.
Viana, F., 2016. TRPA1 channels: molecular sentinels of cellular stress and tissue damage.
J. Physiol. 594, 4151–4169. https://doi.org/10.1113/JP270935.
Volpi, G., Facchinetti, F., Moretto, N., Civelli, M., Patacchini, R., 2011. Cigarette smoke
and α,β-unsaturated aldehydes elicit VEGF release through the p38 MAPK pathway in
human airway smooth muscle cells and lung fibroblasts. Br. J. Pharmacol. 163,
649–661. https://doi.org/10.1111/j.1476-5381.2011.01253.x.
Walls, R.M., Hockberger, R., Gausche-Hill, M., 2017. Rosen's Emergency Medicine:
Concepts and Clinical Practice, 9th ed. Elsevier, Amsterdam.
Wasiak, J., Cleland, H., Campbell, F., Spinks, A., 2013. Dressings for superficial and
partial thickness burns. Cochrane Database Syst. Rev. https://doi.org/10.1002/
14651858.CD002106.pub4.
Weissman-Fogel, I., Dashkovsky, A., Rogowski, Z., Yarnitsky, D., 2008. Vagal damage
enhances polyneuropathy pain: additive effect of two algogenic mechanisms. Pain
138, 153–162. https://doi.org/10.1016/j.pain.2007.11.017.
Xie, B., Xiao, S., Zhu, S., Xia, Z., 2012. Evaluation of long term health-related quality of
life in extensive burns: a 12-year experience in a burn center. Burns 38, 348–355.
https://doi.org/10.1016/j.burns.2011.09.003.
Zimmermann, M., 1983. Ethical guidelines for investigations of experimental pain in
conscious animals. Pain 16, 109–110. https://doi.org/10.1016/0304-3959(83)
90201-4.
Antoniazzi et al. European Journal of Pharmaceutical Sciences 125 (2018) 28–38
38
